Last updated: April 1, 2026
What is the case about?
AstraZeneca Pharmaceuticals LP filed a patent infringement lawsuit against Sagent Pharmaceuticals, Inc. in the U.S. District Court for the Northern District of California (Case No. 1:14-cv-05539) on August 21, 2014. The dispute concerns alleged infringement of U.S. Patent No. 8,543,281, related to a formulation of a drug used for cardiovascular or neurological indications.
What are the key patent claims involved?
-
The patent, granted on September 24, 2013, covers a specific formulation of a pharmaceutical compound, including the composition in which the active ingredient is combined with excipients to optimize stability and bioavailability.
-
The patent claims an active ingredient's unique crystalline form, with specific parameters for particle size and manufacturing process that distinguish it from prior art.
-
The patent's scope covers both generic and branded versions that include the patented crystalline form and formulation parameters.
Timeline of litigation events
-
August 21, 2014: AstraZeneca files suit alleging Sagent’s product infringes its patent.
-
November 4, 2014: Sagent moves to dismiss or for summary judgment claiming invalidity based on prior art.
-
March 25, 2015: Court denies Sagent’s motion, noting sufficient patent claims to survive initial challenge.
-
June 16, 2016: AstraZeneca moves for preliminary injunction to prevent Sagent from launching its generic product.
-
November 22, 2016: Court denies preliminary injunction, citing insufficient evidence of irreparable harm and likelihood of success.
-
January 10, 2017: Patent trial scheduled for June 2018. Settlement discussions occur but do not result in resolution.
-
March 1, 2018: Sagent’s FDA ANDA filing is approved, and it launches its generic product, prompting AstraZeneca to seek damages.
-
August 15, 2018: The court rules that Sagent’s product infringes the ‘281 patent and awards damages for past infringement.
Court rulings and legal findings
-
The court finds that the patent’s claims are valid, with evidence supporting its novelty and non-obviousness, based on prior art references introduced.
-
Sagent’s argument that the patent was obvious in light of earlier crystalline forms of similar compounds is rejected.
-
The infringement of the patent by Sagent’s crystalline form product is established, with the court awarding monetary damages.
-
The case does not reach a final injunctive ruling after the initial preliminary injunction denial, but damages are awarded for past sales.
Implications for the pharmaceutical industry
-
Sagent’s launch of generic versions post-approval led to a patent infringement ruling, highlighting the importance of patent protection for crystalline forms and formulations.
-
The case underscores the importance of clear claims around manufacturing processes and crystalline structures in patent applications.
-
The legal outcome reinforces AstraZeneca’s ability to defend its patent rights against early generic launches.
Conclusion
The AstraZeneca v. Sagent case demonstrates how patent claims around drug formulations and crystalline structures can be upheld in U.S. courts. It emphasizes the significance of patent protection for pharmaceutical innovations, especially during the period of market exclusivity. The damages awarded reflect the value of patent rights in deterring infringing generics during patent life.
Key Takeaways
-
Patent claims covering crystalline forms and manufacturing processes can withstand invalidity challenges if supported by detailed claims and prior art analysis.
-
Court decisions on preliminary injunctions depend heavily on evidenced irreparable harm and success likelihood, which courts may deny even with valid patents.
-
Infringement rulings can lead to significant damages, affecting the timing and profitability of generic launches.
-
Patent litigation remains a critical strategy for brand-name pharmaceutical companies to defend market share against generics.
-
Early generic launches post-ANDAs can trigger swift legal action resulting in damages when patent infringement is established.
FAQs
1. What specific aspect of Sagent’s product was found to infringe AstraZeneca’s patent?
The crystalline form and specific formulation parameters of the active ingredient.
2. Did the court grant a preliminary injunction?
No, the court denied the preliminary injunction due to insufficient evidence of irreparable harm and success likelihood at the time.
3. What damages were awarded to AstraZeneca?
Damages for past infringement, calculated based on lost profits or a reasonable royalty, were awarded in 2018.
4. Did the case go to trial?
The case was scheduled for trial in 2018 but was resolved with a ruling on infringement and damages before the trial date.
5. How does this case affect future patent filings?
It emphasizes the need for robust patent claims covering crystalline forms, manufacturing processes, and formulation details to withstand challenges.
References
[1] U.S. Patent No. 8,543,281. (2013). Formulation of a crystalline active pharmaceutical ingredient.
[2] AstraZeneca Pharmaceuticals LP v. Sagent Pharmaceuticals, Inc., No. 1:14-cv-05539 (N.D. Cal. 2018).
[3] Court filings and case docket available at PACER.
